HLA Hypersensitivity to Carbamazepine and Phenytoin B*1502 Test
Test Name: HLA Hypersensitivity to Carbamazepine and Phenytoin B*1502 Test
Test Components: PCR, Sequencing
Price: AED 1400.0
Sample Condition: 4 mL (3 mL min.) whole blood in 1 Lavender Top (EDTA) tube OR 6 mL (3 mL min.) whole blood in 1 Yellow Top (ACD) tube OR Buccal swab collected in a sterile container. Ship refrigerated. DO NOT FREEZE.
Report Delivery: 10-12 days
Test Type: Disorders of Nervous System, Disorders of Skin
Doctor: Neurologist, Dermatologist
Test Department: Pre Test Information
Pre Test Information: No special preparation required
Overview
The HLA hypersensitivity to carbamazepine and phenytoin (B*15:02) test is a genetic test used to determine an individual’s risk of developing a severe hypersensitivity reaction to the antiepileptic drugs carbamazepine and phenytoin. Carbamazepine and phenytoin are commonly used to treat epilepsy and other neurological conditions. However, in certain individuals, these drugs can cause a severe and potentially life-threatening hypersensitivity reaction known as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).
The HLA-B*15:02 Gene Variant
The HLA-B*15:02 gene variant has been identified as a strong genetic risk factor for the development of SJS/TEN in response to carbamazepine and phenytoin. Individuals who carry this gene variant have a significantly higher risk of developing these severe skin reactions when exposed to these medications.
The Test Process
The HLA hypersensitivity test involves analyzing an individual’s DNA to determine whether they carry the HLA-B*15:02 gene variant. If the gene variant is detected, it indicates an increased risk of developing a severe hypersensitivity reaction to carbamazepine and phenytoin. This information can help healthcare providers make informed decisions about drug selection and avoid prescribing these medications in individuals at high risk.
Important Information
It is important to note that this test is typically recommended before starting carbamazepine or phenytoin treatment, as the risk of developing SJS/TEN is highest during the early stages of drug exposure. If an individual tests positive for the HLA-B*15:02 gene variant, alternative medications can be considered to minimize the risk of a severe hypersensitivity reaction.
Test Name | HLA HYPERSENSITIVITY TO CARBAMAZEPINE and PHENYTOIN B*1502 Test |
---|---|
Components | |
Price | 1400.0 AED |
Sample Condition | 4 mL (3 mL min.) whole blood in 1 Lavender Top (EDTA) tube OR6 mL (3 mL min.) whole blood in 1 Yellow Top (ACD) tube OR Buccal swab collected in a sterile container. Ship refrigerated. DO NOT FREEZE. |
Report Delivery | 10-12 days |
Method | PCR, Sequencing |
Test type | Disorders of Nervous System, Disorders of Skin |
Doctor | Neurologist, Dermatologist |
Test Department: | |
Pre Test Information | No special preparation required |
Test Details | The HLA hypersensitivity to carbamazepine and phenytoin (B*15:02) test is a genetic test used to determine an individual’s risk of developing a severe hypersensitivity reaction to the antiepileptic drugs carbamazepine and phenytoin. Carbamazepine and phenytoin are commonly used to treat epilepsy and other neurological conditions. However, in certain individuals, these drugs can cause a severe and potentially life-threatening hypersensitivity reaction known as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). The HLA-B*15:02 gene variant has been identified as a strong genetic risk factor for the development of SJS/TEN in response to carbamazepine and phenytoin. Individuals who carry this gene variant have a significantly higher risk of developing these severe skin reactions when exposed to these medications. The HLA hypersensitivity test involves analyzing an individual’s DNA to determine whether they carry the HLA-B*15:02 gene variant. If the gene variant is detected, it indicates an increased risk of developing a severe hypersensitivity reaction to carbamazepine and phenytoin. This information can help healthcare providers make informed decisions about drug selection and avoid prescribing these medications in individuals at high risk. It is important to note that this test is typically recommended before starting carbamazepine or phenytoin treatment, as the risk of developing SJS/TEN is highest during the early stages of drug exposure. If an individual tests positive for the HLA-B*15:02 gene variant, alternative medications can be considered to minimize the risk of a severe hypersensitivity reaction. |